• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

CHARLES GROSE, MD
Department of Microbiology and Immunology and Pediatrics Albert Einstein College of Medicine Yeshira University Bronx, NY 10461

Am J Dis Child. 1974;127(3):444.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—There are several omissions in the case report of Guillain-Barré syndrome (GBS) following therapy with mumps-rubella vaccine that was published in the JOURNAL (125:834, 1973) that make the virologic interpretation difficult.

No dates are given for the acute and convalescent sera with respect to the date of immunization.

No rubella antibody titers are given. Since about 7% of recipients of rubella vaccine do not manifest seroconversion, vaccine-rubella infection cannot be assumed in this patient. (Indeed it is noted that he did not develop antibodies to the mumps virus component of the mumps-rubella vaccine.) Without seroconversion, there is little basis for an association of rubella vaccine with the subsequent GBS.

Conversely, very high rubella titers (by hemagglutination-inhibition) in both acute and convalescent sera would suggest an anamnestic antibody response in an immune host. The occurrence of GBS after administration of rubella vaccine in such a patient would be interesting . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?